Novo Holdings A/S Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001388325

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidFocusedHealth TiltHigh Turnover how tags are computed

Q3 2025 · 27 positions · Total reported value $1.55B · Top-10 concentration 73.2% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 40.7% · 2 new · 8 cut · 1 exited

Active Share (vs S&P 500): 99.7% · vs QQQ: 99.3% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -12.9% · vs SPY -15.1% · Prev Value $1.72B — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -0.6% · vs SPY -2.8% · Latest Value $1.49B — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q3 2025 13F filing, Novo Holdings A/S disclosed 27 equity positions with a combined reported value of $1.55B. The filing implies a focused portfolio: its ten largest positions account for 73.2% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2025 were VTI ($340.82M), BN ($159.85M), ASML ($141.18M). By sector, the heaviest allocations are Health Care 40.0%, Technology 14.3%. Versus the prior quarter, allocation shifted toward Health Care (+1.7pp) and away from Technology (-1.6pp).

Versus the prior quarter, Novo Holdings A/S opened 2 new positions, trimmed 8 and fully exited 1, a turnover rate of 40.7% of positions. The portfolio's overlap with the prior quarter was 87% of names.

The largest new positions opened in Q3 2025 were BBOT ($22.71M).

Of the 1 positions fully exited versus the prior quarter, the largest were BPMC ($33.96M), CBLL ($16.86M), ABCL ($2.24M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2025)

  • BBOT BRIDGEBIO ONCOLOGY THERAPEUT · $22.71M

Fully Exited (vs previous quarter)

  • BPMC BLUEPRINT MEDICINES CORP · prev qtr: $33.96M
  • CBLL CERIBELL INC · prev qtr: $16.86M
  • ABCL ABCELLERA BIOLOGICS INC · prev qtr: $2.24M

Insider Transactions (Form 4)

Latest Novo Holdings A/S buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-05-04 Conversion Hemab Therapeutics Holdings, Inc. 4,180,550 — SEC filing
2026-05-01 Buy Avalyn Pharma Inc. 555,555 $18.00 SEC filing
2026-05-01 Conversion Avalyn Pharma Inc. 3,327,734 — SEC filing

All insider transactions →

Fund Profile

Novo Holdings A/S files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q3 2026) lists 26 positions worth $1.49B in total. HoldingsHub carries 13 quarters of its filings (Q3 2023–Q3 2026).

Portfolio Structure

  • 26 positions · $1.49B reported value (Q3 2026)
  • Top 10 holdings = 76.1% of reported value
  • Largest position: EWTX (EDGEWISE THERAPEUTICS INC) at 14.6%
  • Average position size: $57.30M

Sector Tilt

  • Health Care 67.0%
  • Information Technology 17.7%
  • Real Estate 10.9%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q3 2026: 2 new, 6 added, 8 reduced, 1 exited
  • 10 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 40.0%
Technology 14.3%
Real Estate 10.3%
Other 32.2%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 1.04M $340.82M 21.97%
21.97%
Hold
2 2.33M $159.85M 10.30%
10.30%
Hold
3 145.84K $141.18M 9.10%
9.10%
Reduce
4 1.26M $92.67M 5.97%
5.97%
Reduce
5 5.35M $86.78M 5.59%
5.59%
Hold
6 330.19K $78.25M 5.04%
5.04%
Hold
7 750.00K $70.61M 4.55%
4.55%
Hold
8 1.62M $67.68M 4.36%
4.36%
Add
9 2.38M $51.36M 3.31%
3.31%
Hold
10 257.33K $45.99M 2.96%
2.96%
Reduce
11 2.00M $44.40M 2.86%
2.86%
Reduce
12 1.75M $43.66M 2.81%
2.81%
Add
13 7.93M $38.70M 2.49%
2.49%
Reduce
14 1.94M $35.83M 2.31%
2.31%
Add
15 660.00K $35.75M 2.30%
2.30%
Hold
16 916.16K $33.00M 2.13%
2.13%
Hold
17 1.20M $31.04M 2.00%
2.00%
Hold
18 1.43M $29.20M 1.88%
1.88%
Add
19 200.00K $28.80M 1.86%
1.86%
Reduce
20 2.35M $28.61M 1.84%
1.84%
Reduce
21 1.96M $22.71M 1.46%
1.46%
New
22 500.00K $19.86M 1.28%
1.28%
Add
23 2.00M $17.38M 1.12%
1.12%
Hold
24 158.15K $3.88M 0.25%
0.25%
Reduce
25 441.56K $2.33M 0.15%
0.15%
Hold
26 2.51M $912.27K 0.06%
0.06%
Reduce
27 86.58K $322.07K 0.02%
0.02%
Reduce

FAQ

What did Novo Holdings A/S buy in 2025-Q3?

In its 2025-Q3 13F filing, Novo Holdings A/S reported 27 equity positions worth $1.55B in aggregate; its largest disclosed positions were VTI ($340.82M), BN ($159.85M), ASML ($141.18M).

How large is Novo Holdings A/S's portfolio?

Novo Holdings A/S reported $1.55B of long equity holdings across 27 positions as of 2025-Q3. Top-10 holdings account for 73.2% of reported value.

What is Novo Holdings A/S's investment style?

HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/novo-holdings-a-s/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →